Q3 EPS Forecast for WAVE Life Sciences Reduced by Analyst

Key Points

• Analysts at Leerink Partners have downgraded their Q3 2025 EPS forecast for WAVE Life Sciences to ($0.28), slightly below the previous estimate of ($0.27).
• WAVE Life Sciences recently reported Q2 earnings of ($0.31) per share, falling short of the consensus estimate of ($0.29).
• The stock is currently rated as a Moderate Buy by analysts, with an average target price of $20.36.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Analysts at Leerink Partnrs cut their Q3 2025 earnings estimates for shares of WAVE Life Sciences in a research report issued on Wednesday, July 30th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.28) for the quarter, down from their prior estimate of ($0.27). The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for WAVE Life Sciences' Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.15) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($1.12) EPS and FY2027 earnings at ($0.33) EPS.

Several other equities research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of WAVE Life Sciences from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Oppenheimer began coverage on shares of WAVE Life Sciences in a research note on Monday, July 28th. They set an "outperform" rating and a $24.00 target price on the stock. Citigroup began coverage on shares of WAVE Life Sciences in a research note on Wednesday, July 16th. They set a "buy" rating and a $16.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $18.00 target price on shares of WAVE Life Sciences in a research note on Monday, June 23rd. Finally, Raymond James Financial assumed coverage on WAVE Life Sciences in a report on Wednesday, June 11th. They set an "outperform" rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $20.36.

WAVE Life Sciences Stock Up 6.5%

Shares of WVE opened at $8.63 on Monday. WAVE Life Sciences has a 52-week low of $5.04 and a 52-week high of $16.74. The firm's fifty day moving average is $7.22 and its two-hundred day moving average is $8.27. The stock has a market cap of $1.37 billion, a PE ratio of -9.59 and a beta of -0.95.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $11.52 million.

Institutional Trading of WAVE Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of WVE. Adage Capital Partners GP L.L.C. increased its stake in WAVE Life Sciences by 30.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company's stock worth $101,133,000 after purchasing an additional 2,894,396 shares during the period. Price T Rowe Associates Inc. MD increased its stake in WAVE Life Sciences by 63.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock worth $63,074,000 after purchasing an additional 1,972,262 shares during the period. Polar Capital Holdings Plc purchased a new stake in WAVE Life Sciences during the fourth quarter worth about $12,370,000. MPM Bioimpact LLC increased its stake in WAVE Life Sciences by 138.5% during the fourth quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock worth $18,422,000 after purchasing an additional 864,766 shares during the period. Finally, Driehaus Capital Management LLC increased its stake in WAVE Life Sciences by 14.6% during the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock worth $83,033,000 after purchasing an additional 853,589 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at WAVE Life Sciences

In related news, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $6.95, for a total value of $208,500.00. Following the sale, the director directly owned 282,517 shares in the company, valued at approximately $1,963,493.15. The trade was a 9.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 23.98% of the company's stock.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.